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Abstract
Background: Thrombocytopenia is a frequently encountered laboratory abnormality and a
common reason for hematology referrals. Workup for thrombocytopenia is not standardized
and frequently does not follow an evidence-based algorithm. We conducted a systematic analysis to evaluate the laboratory testing and outcomes of patients evaluated for thrombocytopenia at hematology clinics in a tertiary referral center between 2013 and 2016.
Patient and methods: We performed a comprehensive chart review for patients evaluated for
thrombocytopenia during the study period. Patients were followed for 1 year from the initial
hematology evaluation and assessed for the development of a hematologic malignancy,
rheumatologic, or infectious diseases among other clinical outcomes.
Results: We evaluated 472 patients with a median (range) age of 61 (17–94) years. The majority (63.8%) had mild thrombocytopenia. Within 1 year of follow-up, 14 patients (3.0%) were
diagnosed with a hematologic malignancy. A higher likelihood of developing a hematologic
malignancy was noted in patients with concurrent leukopenia (hazard ratio [HR] 9.97, 95% confidence interval [CI] 3.28–30.32, p < .01) and increasing age (HR per 10-year deciles 1.52, 95%
CI 1.03–2.25, p = .03). In patients with asymptomatic isolated mild thrombocytopenia, laboratory testing did not reveal any significant positive findings and patients did not receive any new
major diagnosis during the follow-up period.
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Conclusion: Our findings provide basis and call for development of an evidence-based algorithmic approach for evaluation of patients with thrombocytopenia, testing, and referrals. It also
supports a conservative approach mainly driven by physical exam signs, symptoms, and other
laboratory findings for patients with isolated mild thrombocytopenia.
Ó 2021 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-ncnd/4.0/).

Introduction

Definitions

The normal adult platelet count range is 150–450  109/L,
with mean values of 266  109/L and 237  109/L in females
and males, respectively [1]. Thrombocytopenia, defined as
platelet count <150  109/L, is a frequent reason for hematology consultation as it can be associated with lifethreatening complications (such as bleeding or even thrombosis; e.g., heparin-induced thrombocytopenia) and also
due to concerns about underlying hematologic malignancies, especially when accompanied by other abnormal blood
counts [2,3]. Furthermore, extensive laboratory testing is
usually ordered in an attempt to determine the underlying
pathology. The workup could potentially range from repeating a complete blood count (CBC) and performing a peripheral smear to an extensive evaluation for an underlying
infectious, rheumatologic, or malignant disorder.
We conducted this study to evaluate the laboratory testing initiated by hematologists for patients with thrombocytopenia, as well as the baseline characteristics associated
with certain clinical outcomes in these patients, as a step
towards a standardized approach and evidence-based referral and testing algorithms.

Mild, moderate, and severe thrombocytopenia were defined
as a platelet count of 100–150  109/L, 50–99  109/L, and
<50  109/L, respectively. For patients to be classified
under any category, they had to have at least two values
in the pre-specified range within the previous year. If a
patient had platelet counts that met the criteria for more
than one category, they were considered to be in the more
severe category (e.g., if the patient had two values in the
mild thrombocytopenia range and two values in the moderate thrombocytopenia range, they would be classified as
having moderate thrombocytopenia). Only laboratory tests
or imaging studies that were performed in more than 5%
of patients were included in the analysis. ‘‘Explanation for
thrombocytopenia at 1 year” was defined as a new diagnosis
of hematologic malignancy, immune thrombocytopenic purpura, thrombotic thrombocytopenic purpura, new solid cancer diagnosis, prior or new liver disease, prior or new
rheumatologic disease, infection (e.g., HIV), nutritional
deficiency, pregnancy, end-stage renal disease, drug effect,
spurious result (EDTA-related clumping), or multiple of
these contributing factors.

Methods

Statistical analysis

Patients

For the outcomes of ‘‘new diagnosis of hematologic malignancy” and ‘‘explanation of thrombocytopenia at 1 year”,
a logistic regression model was created and odds ratios
(ORs) were calculated for covariates that were present at
the time of the index visit. Variables with p < .10 in univariate analysis were included in multivariate models. Age was
included as a continuous variable parsed into decades (age
10–19 years, 20–29 years, etc.). ORs and 95% confidence
intervals (CIs) are reported for the logistic regression analyses. Fisher’s exact test was used to compare categorical
variables, where appropriate. Statistics were calculated
using JMP version 14.0, SAS Institute Inc., Cary, NC.

After obtaining approval of the Institutional Review Board
at Henry Ford Health System (Detroit, MI, USA), we
searched for outpatient hematology referrals with a diagnosis of thrombocytopenia using International Classification
of Diseases (ICD-9) and (ICD-10) diagnostic codes for
thrombocytopenia (ICD-9 codes: 287.5, 287.31, 287.49;
ICD-10 codes: D69.6, D69.59) in Henry Ford Hospital
(Detroit, MI, USA) database between June 1, 2013 and
June 1, 2016. Data collected included patient demographics, clinical symptoms and bleeding history, history of
hematologic, rheumatologic, infectious, and chronic liver
diseases, medications, the presence of other abnormalities
on CBC, and laboratory testing performed to investigate
the thrombocytopenia at the time of presentation.
Patients were followed for a period of 1 year from the first
visit with a hematologist (index visit) and were assessed
for development/diagnosis of any of the following outcomes: hematologic malignancy, rheumatologic disorder,
infectious disease, or bleeding. Patients were excluded if
they had any of the following: known hematologic disorder
or malignancy, ongoing chemotherapy, or if they were
seen by a hematologist prior to the index visit for a
platelet-related disorder.

Results
We evaluated 580 patients for thrombocytopenia during the
study period. Of 580 patients, 108 were excluded due to loss
to follow-up, known hematologic disorder or cancer, or
prior known platelet-related disorder. The remaining
patients (n = 472) constituted our cohort with a median
(range) age of 61 (17–94) years, and 282 patients (59.7%)
were males. The majority of patients (n = 274, 58.1%) were
white, followed by African American (n = 140, 29.7%) and
others (n = 58, 12.3%). Regarding the severity of thrombocytopenia, 301 patients (63.8%) had mild thrombocytopenia,
2
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135 patients (28.6%) had moderate thrombocytopenia, and
36 patients (7.6%) had severe thrombocytopenia. Of the
entire cohort, 68 patients (14.4%) were known to have
chronic liver disease (alcoholic, nonalcoholic, or viral) and
34 patients (7.2%) had a history of autoimmune/rheumatologic disease. Sixty patients (12.7%) were on a medication
known to cause thrombocytopenia within a 3-month period
prior to the index visit [4–6]. Chronicity of thrombocytopenia at the time of index visit was divided into three time
periods (<1 years, 1–5 years, and >5 years), with 35.8%,
36.5%, and 27.7% of patients falling in each of these categories, respectively. Patient characteristics parsed according to the severity of thrombocytopenia are shown in
Table 1.
Sixty-seven patients (14.2%) had concurrent leukopenia
(defined as white blood cell count <3.5  109/L) and 130
patients (27.5%) had concurrent anemia (defined as
hemoglobin < 13.5 g/dL in men and < 12 g/dL in women).
The majority of patients (n = 388, 82%) had no history of
bleeding (mucosal bleeding [e.g., mouth, nose, urinary
tract, and gastrointestinal tract], bruising or subcutaneous
bleeding [petechial, purpura, ecchymosis], and/or musculoskeletal bleeding); however, a significantly increased incidence of bleeding symptoms was noted with increasing
severity of thrombocytopenia (8.6%, 31.9%, and 41.7% for
mild, moderate, and severe thrombocytopenia, respectively; p < .01).

Table 1

Race

Age (yr)

Workup ranged from repeating a CBC to a battery of tests
aimed at finding an underlying pathology (including but
not limited to peripheral smear, testing for HIV, viral hepatitis serology, antinuclear antibody [ANA], rheumatoid factor [RF], iron profile [iron, ferritin, total iron binding
capacity], vitamin B12 and folic acid levels, abdominal
ultrasound to evaluate for splenomegaly, protein electrophoresis, immunofixation and immunoglobulin levels,
and bone marrow biopsy).
The most commonly performed tests (>5% of patients)
for each thrombocytopenia severity category and percentage of abnormal results are shown in Table 2. The most frequently performed test was vitamin B12 level; checked in
337 patients (71.4%) and returned abnormal in only 18 of
those patients (5.3%). This was followed by ANA; ordered
for 328 patients (69.5%) with 60 abnormal results (18.3%).
Bone marrow biopsies were performed in 8%, 16.2%, and
63.8% in patients with mild, moderate, and severe thrombocytopenia, respectively.

Outcomes
At the 1-year follow-up mark, 14 patients (3.0%) were diagnosed with a hematologic malignancy as the following:
chronic lymphocytic leukemia/small lymphocytic lymphoma

Patient characteristics.

Patient characteristics

Sex

Laboratory testing

Male
Female
White
African American
Hispanic
Asian
Other/unknown
18–40
41–65
>65

History of liver disease
History of autoimmune disease/rheumatologic disease
Medications known to cause thrombocytopenia
<1
Chronicity of thrombocytopenia (yr)a
1–5
>5
Concurrent leukopeniab
Concurrent anemiac
Symptomsd

Mild thrombocytopenia
(N = 301)

Moderate
thrombocytopenia
(N = 135)

Severe
thrombocytopenia
(N = 36)

189 (62.8)
112 (37.2)
172 (57.1)
86 (28.6)
9 (3)
9 (3)
25 (8.3)
60 (20)
130 (43.1)
111 (36.9)
21 (7)
20 (6.6)
41 (13.6)
117 (38.8)
110 (36.5)
74 (24.5)
38 (12.6)
57 (19)
26 (8.6)

71 (52.6)
64 (47.4)
84 (62)
39 (29)
1 (0.7)
4 (3)
7 (5)
16 (11.8)
71 (53)
48 (35)
36 (26.6)
10 (7.4)
15 (11)
38 (28.1)
49 (36.2)
48 (35.5)
21 (15.5)
53 (38.5)
43 (31.8)

22 (61)
14 (39)
18 (50)
15 (42)
2 (5)
0 (0)
1 (3)
3 (8)
19 (53)
14 (39)
11 (30)
4 (11)
4 (11)
14 (38.9)
13 (36.1)
9 (25)
8 (22.2)
20 (55.5)
15 (41.6)

Note. Data are presented as n (%).
a
An exhaustive list that was adapted from the following references was used to identify medications that can potentially cause
thrombocytopenia [4–6].
b
Defined as a white blood cell count < 3.5  109/L.
c
Defined as haemoglobin <13.5 g/dL in men and <12 g/dL in women.
d
Symptoms include mucosal bleeding (e.g., mouth, nose, urinary tract, and gastrointestinal tract), bruising or subcutaneous bleeding
(petechial, purpura, ecchymosis), and musculoskeletal bleeding. The presence of symptoms was determined based on history rather than
an objective assessment by healthcare provider.
3
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Table 2

Workup for Thrombocytopenia.

Test

ANA
Vitamin B12
MPEV
RF
Viral hepatitis serology
Iron profile
Abdomen ultrasound
HIV
Peripheral smear
Bone marrow biopsy

Mild thrombocytopenia (N = 301)

Moderate thrombocytopenia
(N = 135)

Severe thrombocytopenia
(N = 36)

Tested; n (%)

Abnormal result;
n (% of tested)

Tested; n (%)

Abnormal result;
n (% of tested)

Tested; n (%)

Abnormal result;
n (% of tested)

205 (68)
200 (66)
158 (52)
150 (50)
147 (49)
114 (38)
112 (37)
101 (33)
73 (24)
24 (8)

32 (15.6)
7 (3.5)
12 (7.5)
5 (3.3)
5 (3.4)a
16 (14)
26 (23)
1 (0.3)
2 (2.7)
5 (21)

94 (69.6)
108 (80)
86 (63.7)
68 (50)
85 (63)
78 (57.7)
83 (61.4)
55 (40.7)
51 (37.7)
22 (16.2)

20 (21)
7 (6.5)
0 (0)
4 (6)
10 (12)b
20 (25.6)
25 (30)
0 (0)
6 (11.7)
5 (22.7)

29
29
26
24
31
25
30
21
19
23

8
4
0
2
6
7
9
0
4
3

(80.5)
(80.5)
(72)
(66.6)
(86)
(69.4)
(83.3)
(58.3)
(52.7)
(63.8)

(27.5)
(13.8)
(0)
(8.3)
(19.3)c
(28)
(30)
(0)
(21)
(13)

Note. ANA = antinuclear antibodies; HIV = human immunodeficiency virus; MPEV = monoclonal protein evaluation; RF = rheumatoid factor.
a
Four patients had a known history of chronic viral hepatitis (hepatitis B or C).
b
Eight patients had a known history of chronic viral hepatitis (hepatitis B or C).
c
Five patients had a known history of chronic viral hepatitis (hepatitis B or C).

ative odds of explanation (moderate/severe vs. mild, OR
2.30, 95% CI 1.52–3.48, p < .01) after adjusting for symptoms at the index visit and concurrent anemia, which were
both significant in univariate analysis (Table 3).

(n = 4), large granular lymphocyte leukemia (n = 2), multiple
myeloma (n = 2), myelodysplastic syndrome (n = 2), chronic
myelomonocytic leukemia (n = 1), low-grade B-cell lymphoma (n = 1), marginal zone lymphoma (n = 1), and Tcell acute lymphoblastic leukemia (n = 1). In a multivariate
logistic regression model, patients with concurrent leukopenia (OR 9.97, 95% CI 3.28–30.32, p < .01) and increased age
(OR 1.52 per decade, 95% CI 1.03–2.25, p = .03) had a significantly increased relative odds of having a newly diagnosed hematologic malignancy at 1 year (Table 3). Of
note, all 14 patients diagnosed with a hematologic malignancy had other constitutional symptoms, signs, abnormal
blood counts, and/or imaging studies besides thrombocytopenia that warranted further workup at time of initial
evaluation (Table 4).
Five patients (1.1%) were diagnosed with a new infectious disease: hepatitis B/C (n = 3), HIV (n = 1), and infectious mononucleosis caused by Epstein–Barr virus (n = 1).
One patient (0.2%) had a new rheumatologic diagnosis
(mixed connective tissue disease). Six patients (1.3%) had
minor bleeding (cutaneous bruising, mild menorrhagia, and
hemorrhoidal bleeding); no patients had significant bleeding
that required transfusion of blood products. Other notable
hematologic diagnoses included 20 patients with immune
thrombocytopenic purpura, 10 patients with monoclonal
gammopathy of undetermined significance, and one patient
with thrombotic thrombocytopenic purpura. Six patients
(1.3%) were diagnosed with solid malignancies as the result
of further workup. Two patients (0.4%) had newly diagnosed
nonalcoholic fatty liver disease diagnosed after further
workup.
Taken together, 192/472 patients (40.7%) had a putative
explanation for thrombocytopenia after 1 year of follow-up
(Fig. 1), whereas 280/472 patients (59.3%) did not develop
any new clinical condition or have any identified underlying
factor that could explain the thrombocytopenia within
1 year of the index visit. In a multivariate logistic regression
model for explanation for thrombocytopenia at 1 year,
severity of thrombocytopenia had a significantly higher rel-

Discussion
Hematology referrals for thrombocytopenia constitute a significant portion of patients seen in a general hematology
clinic. In our study, we examined the laboratory testing
and clinical outcomes for 472 patients who were evaluated
for thrombocytopenia in hematology subspecialty clinics at
a tertiary center. We noted that having moderate to severe
thrombocytopenia (<99  109/L) was associated with a
higher likelihood of having an explanation for thrombocytopenia at 1 year. We also noted that both having concurrent leukopenia along with thrombocytopenia and
increasing age significantly increased the relative odds of
receiving a diagnosis of a hematologic malignancy within
1 year and a more extensive and invasive workup (i.e., bone
marrow biopsy, etc.) can be considered in such patients. It
is also important to note that the majority of patients
(280/472 [59.3%]) did not have any explanation for their
thrombocytopenia at the 1-year mark.
When we examine the tests performed for each thrombocytopenia category, we notice that the majority of the tests
had a positive yield of <20% and in some occasions 0%, even
though the test was performed in over 60–70% of the study
cohort. Some tests, like the ANA screen, had a higher percentage of positive results (18%) without any subsequent
change in management, additional workup, or increased
likelihood of receiving a rheumatologic diagnosis at
follow-up. A similar pattern is seen with RF, which was
tested in over 50% of the study cohort, with just 7% of these
patients having a positive result; none of these patients had
a subsequent change in management, likely due to lack of
symptoms that could prompt further workup. Only one
patient received a rheumatologic diagnosis at the 1-year
4
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0.81
1.05 (0.72–1.54)
1.00 (0.33–3.02)
169/472 (36)

0.99

<0.01
9.97 (3.28–30.32)

follow-up mark (mixed connective tissue disease). Interestingly, this patient had significant fatigue and arthralgia in
addition to mild thrombocytopenia, prompting further
investigation for an underlying rheumatologic/autoimmune
process.
Bone marrow biopsies were performed more often on
patients with severe thrombocytopenia (64%) than on those
with moderate (16%) and mild (8%) thrombocytopenia
(Table 2). Of the patients with mild thrombocytopenia
who had a bone marrow biopsy, five patients (21%) were
diagnosed with a hematologic malignancy. Although this
appears to be a high percentage for patients with mild
reduction in platelet counts, all five patients had other concurrent hematologic abnormalities (anemia and/or leukopenia) or other clinically relevant symptoms that prompted
the biopsy. Patients who had a bone marrow biopsy were
also older (69 years vs. 61 years). Therefore, the procedure
was directed at a high-risk subset of patients with mild
thrombocytopenia and the high percentage of patients with
a hematologic malignancy out of those who had bone marrow biopsies should not be generalized to all patients with
mild thrombocytopenia.
As for infectious etiologies, testing for viral hepatitis was
performed in 263 patients (50%) of our study population,
and was able to detect four new cases of chronic viral hepatitis (B or C). Testing for HIV was performed in 37.5% of
patients and was able to detect a single case of HIV. Despite
the low yield of testing for infectious etiologies, these findings should not discourage providers from testing for viral
hepatitis and HIV in patients with thrombocytopenia, especially as the Centers for Disease Control and Prevention
(CDC) recommends routine screening for HIV infection for
all patients aged 13–64 years [7], and routine screening
for all patients born between 1945 and 1965 or those with
risk factors for hepatitis C virus [8].
Referral to a hematologist is appropriate to confirm any
new diagnosis in a patient with thrombocytopenia or to
determine the cause of any unexplained thrombocytopenia,
especially in cases of moderate to severe thrombocytopenia. Hematology referrals for asymptomatic mild thrombocytopenia have always been an area of debate; some
studies have shown that as low as 3% of these patients
required an intervention by a hematologist and normalization of platelet counts within 1 month in patients with normal bleeding history and no positive physical examination
findings [9]. Another study showed that 11% of patients normalized their platelet counts, <1% developed a hematologic
malignancy or an autoimmune disorder, and the majority
(88%) had stable platelet counts during the 6-month monitoring period. Interestingly, a 12% 10-year probability of
developing an autoimmune disease (other than immune
thrombocytopenic purpura) was noted [10].
Our study also supports the need for a cost-effective
analysis for patients with thrombocytopenia given the low
yield and high cost for most tests ordered for these patients.
Although such studies are limited given the broad population and the variety of tests ordered, cost-effective analyses have been performed in populations who had specific
tests for specific disorders (e.g., HIT antibodies for
heparin-induced thrombocytopenia) [11,12]. These studies
reached conclusions consistent with our findings: an
approach of informed testing guided by signs, symptoms,

Note. CI = confidence interval; HR = hazard ratio. Bold font denotes significance in the multivariate model.
a
Defined as a new diagnosis of hematologic malignancy, medication attributable effect, other hematologic diagnosis (e.g., Idiopathic thrombocytopenic purpura (ITP)), new solid cancer
diagnosis, liver disease, rheumatologic disease, infection (e.g., HIV), nutritional deficiency, pregnancy, end-stage renal disease, spurious result (EDTA-clumping), or multiple of these.
b
Forward selection method employed whereby any variable with p < .10 in univariate analysis was included in the multivariate model.
c
For the multivariate models for ‘‘Explanation of Thrombocytopenia at 1 year,” ‘‘Moderate/Severe” thrombocytopenia severity was used.

0.54

1.28 (0.83–1.97)

0.69
0.60
0.02
0.84
0.03
(0.92–1.14)
(0.62–1.32)
(1.08–2.44)
(0.62–1.78)
(1.05–2.70)
1.02
0.91
1.62
1.06
1.68
0.03
1.52 (1.03–2.25)

0.05
0.37
0.49
<0.01
0.72
1.46
1.71
1.48
9.02
1.27
n/a
282/472 (60)
130/472 (28)
67/472 (14)
84/472 (18)

(1.00–2.12)
(0.53–5.53)
(0.49–4.50)
(3.02–26.91)
(0.35–4.65)

2.08 (0.45–9.67)
2.41 (0.82–7.08)

Severity of thrombocytopenia
Severe (<50 k vs. 50–150 k)
Moderate/severe (<100 k vs.
100–150 k)c
Age (HR per 10-yr deciles)
Sex (male vs. female)
Concurrent anemia
Concurrent leukopenia
Symptoms (mucosal bleeding,
bruising)
Duration of thrombocytopenia
(<1 yr vs.  1 yr)

36/472 (8)
171/472 (36)

0.35
0.11

1.17 (0.70–1.95)

0.26

<0.01
2.30 (1.52–3.48)
<0.01
<0.01
3.66 (1.80–7.93)
2.53 (1.72–3.72)

Multivariateb HR
(95% CI)
p
Univariate HR (95% CI)
p

Multivariateb HR
(95% CI)

p

Explanation for thrombocytopenia at 1 yra
Hematologic malignancy at 1 yr

Univariate HR
(95% CI)
n/N (%)
Variable

Table 3

Logistic Regression Analysis Showing Associations of Development of Hematologic Malignancy and/or Explanation for the Thrombocytopenia at 1 year.

p
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Table 4

Other Hematologic Abnormalities, Signs, or Symptoms in Patients with New Hematologic Malignancy.

Patient

Thrombocytopenia
severity at presentation

Symptoms and signs

Other laboratory abnormalities

CLL/SLL – 1

Mild

Leukocytosis/lymphocytosis

CLL/SLL – 2
CLL/SLL – 3
CLL/SLL – 4
Chronic myelomonocytic leukemia
LGL leukemia – 1
LGL leukemia – 2
Low-grade B-cell lymphoma
Marginal zone lymphoma
Myelodysplastic syndrome – 1
Myelodysplastic syndrome – 2
Multiple myeloma – 1
Multiple myeloma – 2
T-ALL

Mild
Moderate
Moderate
Moderate
Severe
Moderate
Moderate
Mild
Mild
Moderate
Mild
Mild
Severe

Night sweats and
lymphadenopathy
None
None
Splenomegaly
Bruising, splenomegaly
Mucosal bleeding
None
None
30 lbs. weight loss
None
None
None
None
Constitutional symptoms

Leukocytosis/lymphocytosis
Leukocytosis/lymphocytosis
Leukocytosis/lymphocytosis
Anemia, leukopenia
Leukopenia
Leukopenia
Leukopenia
None
Anemia, leukopenia
Anemia, leukopenia
Anemia, leukopenia
Leukopenia
Anemia, leukopenia

Note. CBC = complete blood count; CLL/SLL = chronic lymphocytic leukemia/small lymphocytic lymphoma; HIV = human immunodeficiency virus; LFT = liver function test; LGL = large granular lymphocytic leukemia; T-ALL = T-cell acute lymphoblastic leukemia.

[14], as the study was conducted in a major liver transplant
center. All these factors can have a significant effect on the
various etiologies of thrombocytopenia in our study compared with populations in different geographical regions
across the country. Finally, the workup was subject to decisions of individual hematologists and not standardized for
the 472 patients, leaving the possibility that some potential
diagnoses were undetected. Furthermore, several clonal
disorders have recently been recognized and described,
but these require laboratory testing platforms that had
not been implemented during the study period (i.e., clonal

and laboratory findings and based on pre-test probability is
preferred to a gunshot approach in low-risk populations.
We acknowledge that there are several limitations to our
study, the first being the retrospective nature of the analysis. In addition, our study examines a racially diverse urban
city population [13], where environmental, socioeconomic,
and ethnic factors could have a potential influence on the
etiology or even normal variation in platelet counts. The
study population is also skewed towards a cohort with
higher rates of alcohol abuse and chronic alcoholic or viral
liver disease (14.4% vs. 1.8% for the general US population)

Fig. 1 Confirmed/plausible explanations of thrombocytopenia at 1 year in 192/472 patients (40.7%) with degree of
thrombocytopenia at presentation. Note. ESRD = end-stage renal disease; ITP = idiopathic thrombocytopenic purpura;
TTP = thrombotic thrombocytopenic purpura. There was no clear explanation for thrombocytopenia at 1 year in 280/472 patients
(59.3%; not shown in this figure).
6
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[5] George JN, Raskob GE, Shah SR, Rizvi MA, Hamilton SA,
Osborne S, et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med
1998;129:886–90.
[6] Arnold DM, Nazi I, Warkentin TE, Smith JW, Toltl LJ, George
JN, et al. Approach to the diagnosis and management of druginduced immune thrombocytopenia. Transfus Med Rev
2013;27:137–45.
[7] Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW,
Lyss SB, et al. Revised recommendations for HIV testing of
adults, adolescents, and pregnant women in health-care
settings. Available from: https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5514a1.htm; 2006 [accessed 2 February
2021].
[8] Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D,
Teo CG, et al. Recommendations for the identification of
chronic hepatitis C virus infection among persons born during
1945–1965. MMWR Recomm Rep 2012;61:1–32.
[9] Schlappi C, Kulkarni V, Palabindela P, Bemrich-Stolz C, Howard
T, Hilliard L, et al. Outcomes in mild to moderate isolated
thrombocytopenia. Pediatrics 2018;142. https://doi.org/
10.1542/peds.2017-3804.
[10] Stasi R, Amadori S, Osborn J, Newland AC, Provan D. Long-term
outcome of otherwise healthy individuals with incidentally
discovered borderline thrombocytopenia. PLoS Med 2006;3:
e24. https://doi.org/10.1371/journal.pmed.0030024.
[11] Patrick AR, Winkelmayer WC, Avorn J, Fischer MA. Strategies
for the management of suspected heparin-induced thrombocytopenia: a cost-effectiveness analysis. Pharmacoeconomics
2007;25:949–61.
https://doi.org/10.2165/00019053200725110-00005.
[12] Hasan M, Malalur P, Agastya M, Malik AO, Dawod Y, Jaradat M,
et al. A high-value cost conscious approach to minimize
heparin induced thrombocytopenia antibody (HITAb) testing
using the 4T score. J Thromb Thrombolysis 2016;42:441–6.
https://doi.org/10.1007/s11239-016-1396-6.
[13] Wayne County Michigan (MI). http://www.city-data.com/county/Wayne_County-MI.html [accessed 19 March 2020].
[14] Centers for Disease Control and Prevention. Chronic liver
disease and cirrhosis - https://www.cdc.gov/nchs/fastats/
liver-disease.htm [accessed 2 February 2021].

hematopoiesis of unknown significance [CHIP], clonal
cytopenia of undetermined significance [CCUS], and idiopathic cytopenia of undetermined significance [ICUS]).
In conclusion, thrombocytopenia is a frequent laboratory
finding prompting referral to hematology subspecialty clinics. Outcomes of patients with thrombocytopenia vary
based on severity with a higher likelihood of finding a putative explanation at 1 year in patients with moderate to severe thrombocytopenia. Concurrent leukopenia and
increasing age were independently associated with higher
relative odds of being diagnosed with a hematologic malignancy at 1 year. Lastly, in asymptomatic patients with mild
thrombocytopenia, laboratory testing did not reveal any
major positive findings and patients did not develop any significant hematologic, infectious, or rheumatologic disorders
within 1 year of follow-up. Our study also demonstrates the
need for an algorithmic evidence-based approach for referral and testing for thrombocytopenia.
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